FibroGen Inc (NASDAQ: FGEN) on Tuesday, plunged -3.22% from the previous trading day, before settling in for the closing price of $0.32. Within the past 52 weeks, FGEN’s price has moved between $0.18 and $1.53.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -35.07% annually for the last half of the decade. The company achieved an average annual earnings per share of -1.04%. With a float of $94.08 million, this company’s outstanding shares have now reached $101.04 million.
In an organization with 225 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 57.78%, operating margin of 570.33%, and the pretax margin is 580.39%.
FibroGen Inc (FGEN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of FibroGen Inc is 6.90%, while institutional ownership is 32.66%. The most recent insider transaction that took place on Mar 24 ’25, was worth 50,663. In this transaction CEO of this company bought 145,000 shares at a rate of $0.35, taking the stock ownership to the 543,329 shares. Before that another transaction happened on Mar 20 ’25, when Company’s Director bought 250,000 for $0.35, making the entire transaction worth $88,000. This insider now owns 323,722 shares in total.
FibroGen Inc (FGEN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -10.06% during the next five years compared to 11.75% growth over the previous five years of trading.
FibroGen Inc (NASDAQ: FGEN) Trading Performance Indicators
FibroGen Inc (FGEN) is currently performing well based on its current performance indicators. A quick ratio of 1.98 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.10, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.72 in one year’s time.
Technical Analysis of FibroGen Inc (FGEN)
Let’s dig in a bit further. During the last 5-days, its volume was 0.75 million. That was inferior than the volume of 2.3 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 66.43%. Additionally, its Average True Range was 0.02.
During the past 100 days, FibroGen Inc’s (FGEN) raw stochastic average was set at 12.23%, which indicates a significant decrease from 38.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.88% in the past 14 days, which was lower than the 110.02% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3056, while its 200-day Moving Average is $0.3915.
